Fig. 5

Effects of minocycline and STAT3 inhibitor on the survival rates of CD133⁺ and CD133⁻ cells from C6 glioma cells. (a and b) CD133⁺ and CD133⁻ cells were treated with Mino (25 μM) (a) or WP1066 (5 μM) (b) for 48 h and cell viability was assessed using the WST-1 assay. **p < 0.01, ***p < 0.001 CD133⁺vs. CD133⁻. c Western blotting analysis of p-STAT3 and STAT3 in CD133⁺, CD133⁻, and their parent cells from C6 glioma cells. d The phosphorylated states of STAT3 in CD133⁺ were markedly inhibited by STAT3 inhibitors WP1066 and S3 l-201. e Cancer stem cell markers Nestin, SSES-1, and NANOG in CD133⁺ were markedly inhibited by STAT3 inhibitor WP1066